Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 10/2014

01.10.2014 | Original Article

Bridging cross-cultural gaps: monitoring herbal use during chemotherapy in patients referred to integrative medicine consultation in Israel

verfasst von: Limor Almog, Efraim Lev, Elad Schiff, Shai Linn, Eran Ben-Arye

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The high prevalence of the use of traditional herbs among patients with cancer is a cause for concern with regard to potentially adverse interactions with conventional oncology treatments. In this study, we explore herbal use among patients with cancer in northern Israel who are referred by their health care providers to complementary and traditional medicine (CTM) consultations provided to them within the conventional oncology department. The study’s objectives were to identify which herbs patients use and to examine the scope of current research on the efficacy and safety regarding the identified herbs.

Patients and methods

Herbal use by patients receiving oncology care was assessed prospectively from July 2009 to July 2012 by integrative physicians (IPs) trained in herbal medicine. Historical, ethnobotanical, basic research, and clinical data regarding the identified herbs were explored by using a keyword search in PubMed and Middle Eastern ethnohistorical literature.

Results

Disclosure of herbal use was reported by 154 of the 305 patients (50.5 %) interviewed by IPs. The use of 85 single herbs and 30 different herbal formulas was documented during the initial or follow-up IP assessments. Patients reported 14 quality of life-associated indications for herbal use. The ten most prevalent herbs displaying in vitro/in vivo anticancer activity and nine other herbs were preliminarily assessed concerning potential risks, safety, and interaction with chemotherapy.

Conclusions

Herbal use by patients with cancer in northern Israel is widespread and calls for further study in order to address issues of safety and effectiveness. We recommend constructing a multinational and multidisciplinary team of researchers with ethnopharmacological and clinical expertise that will explore the use of herbs among patients with cancer in a cross-cultural perspective attuned with patients’ affinity to traditional herbal medicine.
Literatur
1.
Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M (2012) How many cancer patients use complementary and alternative medicine? A systematic review and meta-analysis. Integr Cancer Ther 11(3):187–203PubMedCrossRef
2.
Inanç N, Sahin H, Çiçek B, Tasc S (2006) Use of herbs or vitamin/mineral supplements by patients with cancer in Kayseri, Turkey. Cancer Nurs 29(1):17–20PubMedCrossRef
3.
Afifi FU, Wazaify M, Jabr M, Treish E (2010) The use of herbal preparations as complementary and alternative medicine (CAM) in a sample of patients with cancer in Jordan. Complement Ther Clin Pract 16(4):208–212PubMedCrossRef
4.
Ben-Arye E, Massalha E, Bar-Sela G, Silbermann M, Agbarya A, Saad B, Lev E, Schiff E. Stepping from traditional to integrative medicine: perspectives of Israeli-Arab patients on complementary medicine’s role in cancer care. (Accepted to Annals of Oncology.)
5.
Ali-Shtayeh MS, Jamous RM, Jamous RM (2011) Herbal preparation use by patients suffering from cancer in Palestine. Complement Ther Clin Pract 17(4):235–240PubMedCrossRef
6.
Barton DL, Soori GS, Bauer BA, Sloan JA, Johnson PA, Figueras C et al (2010) Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 18(2):179–187PubMedCentralPubMedCrossRef
7.
Ryan JL, Heckler CE, Roscoe JA, Dakhil SR, Kirshner J, Flynn PJ et al (2012) Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer 20(7):1479–1489PubMedCentralPubMedCrossRef
8.
Guo L, Bai SP, Zhao L, Wang XH (2012) Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. Med Oncol 29(3):1656–1662PubMedCrossRef
9.
Pittler MH, Ernst E (2003) Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 18(5):451–471PubMedCrossRef
10.
Posadzki P, Watson LK, Ernst E (2013) Adverse effects of herbal medicines: an overview of systematic reviews. Clin Med 13(1):7–12PubMedCrossRef
11.
Sparreboom A, Cox MC, Acharya MR, Figg WD (2004) Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22(12):2489–2503PubMedCrossRef
12.
Engdal S, Klepp O, Nilsen OG (2009) Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther 8(1):29–36PubMedCrossRef
13.
Komoroski BJ, Parise RA, Egorin MJ, Strom SC, Venkataramanan R (2005) Effect of the St. John’s wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin Cancer Res 11(19 Pt 1):6972–6979PubMedCrossRef
14.
Etheridge AS, Kroll DJ, Mathews JM (2009) Inhibition of paclitaxel metabolism in vitro in human hepatocytes by Ginkgo biloba preparations. J Diet Suppl 6(2):104–110PubMedCrossRef
15.
Ben-Arye E, Schiff E, Zollman C, Heusser P, Mountford P, Frenkel M et al (2013) Integrating complementary medicine in supportive cancer care models across four continents. Med Oncol 30(2):511PubMedCrossRef
16.
Ben-Arye E, Schiff E, Shapira C, Frenkel M, Shalom T, Steiner M (2012) Modeling an integrative oncology program within a community-centered oncology service in Israel. Patient Educ Couns 89(3):423–429PubMedCrossRef
17.
Lev E, Amar Z (2008) Practical Materia Medica of the Medieval Eastern Mediterranean according to the Cairo Genizah. Brill, Leiden
18.
Hessissen L, Bhour M, El Kababri M, Kili A, Nachef M, Elkhorassani M et al (2011) Utilisation de la médecine alternative en oncologie pédiatrique au maroc. J Afr Cancer Afr J Cancer 3(3):163–168CrossRef
19.
Naja F, Alameddine M, Abboud M, Bustami D, R. AH (2011) Complementary and alternative medicine use among pediatric patients with leukemia: the case of Lebanon. Integr Cancer Ther 10(1):38–46PubMedCrossRef
20.
Algier LA, Hanoglu Z, Özden G, Kara F (2005) The use of complementary and alternative (non-conventional) medicine in cancer patients in Turkey. Eur J Oncol Nurs 9(2):138–146PubMedCrossRef
21.
Gözüm S, Tezel A, Koc M (2003) Complementary alternative treatments used by patients with cancer in eastern Turkey. Cancer Nurs 26(3):230–236PubMedCrossRef
22.
Bar-Sela G, Tsalic M, Fried G, Goldberg H (2007) Wheat grass juice may improve hematological toxicity related to chemotherapy in breast cancer patients: a pilot study. Nutr Cancer 58(1):43–48PubMedCrossRef
23.
Bonfili L, Amici M, Cecarini V, Cuccioloni M, Tacconi R, Angeletti M, Fioretti E, Keller JN, Eleuteri AM (2009) Wheat sprout extract-induced apoptosis in human cancer cells by proteasomes modulation. Biochimie 91(9):1131–1144PubMedCrossRef
24.
Peryt B, Szymcyzyk T, Lesca P (1992) Mechanism of antimutagenicity of wheat sprout extracts. Mutat Res 269(2):201–215PubMedCrossRef
25.
Arya P, Kumar M (2011) Chemoprevention by Triticum aestivum of mouse skin carcinogenesis induced by DMBA and croton oil—association with oxidative status. Asian Pac J Cancer Prev 12(1):143–148PubMed
26.
Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Manett LJ, Gescher AJ, Steward WP (2001) Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 7(7):1894–1900PubMed
27.
28.
Bayet-Robert M, Kwiatowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, Mouret-Revnier MA, Durando X, Barthomeuf C, Chollet P (2010) Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9(1):8–14PubMedCrossRef
29.
Lev-Ari S, Maimon Y, Strier L, Kazanov D, Arber N (2005) Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J Soc Integr Oncol 4(1):21–26
30.
Chiu T, Su C (2009) Curcumin inhibits proliferation and migration by increasing the bax to bcl-2 ratio and decreasing NF-κBp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med 23(4):469PubMed
31.
Huang AC, Lin SY, Su CC, Lin SS, Ho CC, Hsia TC, Chiu YH, Yu CS, Ip SW, Lin TP, Chung JG (2008) Effects of curcumin on N-bis(2-hydroxypropyl) nitrosamine (DHPN)-induced lung and liver tumorigenesis in BALB/c mice in vivo. In Vivo 22(6):781–785PubMed
32.
Levey M (1966) The Medical Formulary or the Aqrabadhin of Al-Kindi. Madison.
33.
Hanley M, Masse G, Harmatz J (2012) Pomegranate juice and pomegranate extract do not impair oral clearance of flurbiprofen in human volunteers: divergence from in vitro results. Clin Pharmacol Ther 92(5):651–657PubMedCrossRef
34.
Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A (2006) Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 12(13):4018–4026PubMedCrossRef
35.
Kasimsetty SG, Bialonska D, Reddy MK, Ma G, Khan SI, Ferreira D (2010) Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins. J Agric Food Chem 58(4):2180–2187PubMedCrossRef
36.
Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H et al (2008) Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther 7(9):2662–2671PubMedCentralPubMedCrossRef
37.
Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H (2005) Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci U S A 102(41):14813–14818PubMedCentralPubMedCrossRef
38.
Pikel A (1997) The traditional natural medicine of the Iranian Jews. Kochav Yaa‘kov (Hebrew).
39.
Borgelt LM, Franson KL, Nussbaum AM, Wang GS (2013) The pharmacologic and clinical effects of medical cannabis. Pharmacother Pharmacother 33(2):195–209CrossRef
40.
Machado Rocha FC, Stefano S, De Cassia Haiek R, Rosa Oliveira L, Da Silveira D (2008) Therapeutic use of Cannabis sativa on chemotherapy‐induced nausea and vomiting among cancer patients: systematic review and meta‐analysis. Eur J Cancer Care 17(5):431–443CrossRef
41.
Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A (2011) Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 10(7):1161–1172PubMedCrossRef
42.
Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Díaz-Laviada I (2011) Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 18(7):1099–1111PubMedCentralPubMedCrossRef
43.
Kienle GS, Grugel R, Kiene H (2011) Safety of higher dosages of Viscum album L. in animals and humans—systematic review of immune changes and safety parameters. BMC Complement Altern Med 11:72PubMedCentralPubMedCrossRef
44.
Kienle GS, Kiene H (2007) Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 12(3):103–119PubMed
45.
Horneber MA, Bueschel G, Huber R, Linde K, Rostock M (2008) Mistletoe therapy in oncology. Cochrane Database Syst Rev 2:CD003297PubMed
46.
Semiglazov V, Stepula V, Dudov A, Schnitker J, Mengs U (2006) Quality of life is improved in breast cancer patients by standardised mistletoe extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 26(2B):1519–1529PubMed
47.
Kim KC, Yook JH, Eisenbraun J, Kim BS, Huber R (2012) Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma—a randomized, controlled pilot study. BMC Complement Altern Med 12:172PubMedCentralPubMedCrossRef
48.
Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS (2004) Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24(1):303–309PubMed
49.
Ziegler R, Grossarth-Maticek R (2010) Individual patient data meta-analysis of survival and psychosomatic self-regulation from published prospective controlled cohort studies for long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Evid Based Complement Alternat Med 7(2):157–166PubMedCentralPubMedCrossRef
50.
Grossarth-Maticek R, Ziegler R (2007) Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). Forsch Komplement Med 14(3):140–147CrossRef
51.
Grossarth-Maticek R, Ziegler R (2007) Prospective controlled cohort studies on long-term therapy of ovarian cancer patients with mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung 57(10):665–678PubMed
52.
Grossarth-Maticek R, Ziegler R (2008) Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Eur J Med Res 13(3):107–120PubMed
53.
Cazacu M, Oniu T, Lungoci C, Mihailov A, Cipak A, Klinger R, Weiss T, Zarkovic N (2003) The influence of Isorel on the advanced colorectal cancer. Cancer Biother Radiopharm 18(1):27–34PubMedCrossRef
54.
Augustin M, Bock PR, Hanisch J, Karasmann M, Schneider B (2005) Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Arzneimittelforschung 55(1):38–49PubMed
55.
Khil LY, Kim W, Lyu S, Park WB, Yoon JW, Jun HS (2007) Mechanisms involved in Korean mistletoe lectin-induced apoptosis of cancer cells. World J Gastroenterol 13(20):2811–2818PubMed
56.
Valentiner U, Pfuller U, Baum C, Schumacher U (2002) The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro. Toxicology 171(2–3):187–199PubMedCrossRef
57.
Elluru SR, Duong Van Huyen JP, Delignat S, Prost F, Heudes D, Kazatchkine MD, Friboulet A, Kaverl SV (2009) Antiangiogenic properties of Viscum album extracts are associated with endothelial cytotoxicity. Anticancer Res 29(8):2945–2950PubMed
58.
Kovacs E (2002) The in vitro effect of Viscum album (VA) extract on DNA repair of peripheral blood mononuclear cells (PBMC) in cancer patients. Phytother Res 16(2):143–147PubMedCrossRef
59.
Kahl O (2003) Sabur ibn Sahl, The small dispensatory (trans.), Leiden-Boston.
60.
Mason JK, Chen J, Thompson LU (2010) Flaxseed oil-trastuzumab interaction in breast cancer. Food Chem Toxicol 48(8–9):2223–2226PubMedCrossRef
61.
Rahman S, Salehin F, Iqbal A (2011) In vitro antioxidant and anticancer activity of young Zingiber officinale against human breast carcinoma cell lines. BMC Complement Altern Med 11:76PubMedCentralPubMedCrossRef
62.
Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT 4th, Snyder DC, Owzar K, Hars V, Albala DM, Walther PJ, Robertson CN, Moul JW, Dunn BK, Brenner D, Minasian L, Stella P, Vollmer RT (2008) Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev 17(12):3577–3587PubMedCentralPubMedCrossRef
63.
Danbara N, Yuri T, Tsujita-Kyutoku M, Tsukamoto R, Uehara N, Tsubura A (2005) Enterolactone induces apoptosis and inhibits growth of Colo 201 human colon cancer cells both in vitro and in vivo. Anticancer Res 25(3B):2269–2276PubMed
64.
Truan JS, Chen JM, Thompson LU (2010) Flaxseed oil reduces the growth of human breast tumors (MCF-7) at high levels of circulating estrogen. Mol Nutr Food Res 54(10):1414–1421PubMedCrossRef
65.
66.
Kahl O. (ed. and trans.). Sābūr ibn Sahl’s dispensatory in the Recension of the Adudī Hospital. Leiden; Boston: Brill.2009.
67.
Amar Z (2003) Pri Megadim of Rabbi David de Silva (Hebrew). Jerusalem.
68.
Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C (2007) Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: A longitudinal analysis. Pharmacotherapy 27(9):1237–1247PubMedCrossRef
69.
Rhode J, Fogoros S, Zick S, Wahl H, Griffith KA, Huang J, Liu JR (2007) Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells. BMC Complement Altern Med 7:44PubMedCentralPubMedCrossRef
70.
Karna P, Chagani S, Gundala SR, Rida PC, Asif G, Sharma V, Gupta MV, Aneia R (2012) Benefits of whole ginger extract in prostate cancer. Br J Nutr 107(4):473–484PubMedCentralPubMedCrossRef
71.
Pillai AK, Sharma KK, Gupta YK, Bakhshi S (2011) Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer 56(2):234–238. doi:10.​1002/​pbc.​22778 PubMedCrossRef
72.
Ramos AA, Pedro D, Collins AR, Pereira-Wilson C (2012) Protection by salvia extracts against oxidative and alkylation damage to DNA in human HCT15 and CO115 cells. J Toxicol Environ Health A 75(13–15):765–775PubMedCrossRef
73.
Kianbakht S, Abasi B, Perham M, Hashem Dabaghian F (2011) Antihyperlipidemic effects of Salvia officinalis L. leaf extract in patients with hyperlipidemia: a randomized double-blind placebo-controlled clinical trial. Phytother Res 25(12):1849–1853PubMedCrossRef
74.
Kapadia GJ, Azuine MA, Rao GS, Arai T, Iida A, Tokuda H (2011) Cytotoxic effect of the red beetroot (Beta vulgaris L.) extract compared to doxorubicin (adriamycin) in the human prostate (PC-3) and breast (MCF-7) cancer cell lines. Anti Cancer Agents Med Chem 11(3):280–284CrossRef
75.
Lima CF, Fernandes-Ferreira M, Pereira-Wilson C (2007) Drinking of Salvia officinalis tea increases CCl(4)-induced hepatotoxicity in mice. Food Chem Toxicol 45(3):456–464PubMedCrossRef
76.
Xavier CP, Lima CF, Fernandes-Ferreira M, Pereira-Wilson C (2009) Salvia fruticosa, Salvia officinalis, and rosmarinic acid induce apoptosis and inhibit proliferation of human colorectal cell lines: the role in MAPK/ERK pathway. Nutr Cancer 61(4):564–571PubMedCrossRef
77.
Keshavarz M, Mostafaie A, Mansouri K, Bidmeshkipour A, Motlagh HR, Parvaneh S (2010) In vitro and ex vivo antiangiogenic activity of Salvia officinalis. Phytother Res 24(10):1526–1531PubMedCrossRef
78.
Vandecasteele K, Ost P, Oosterlinck W, Fonteyne V, Neve WD, Meerleer GD (2012) Evaluation of the efficacy and safety of Salvia officinalis in controlling hot flashes in prostate cancer patients treated with androgen deprivation. Phytother Res 26(2):208–213PubMedCrossRef
79.
Kaileh M, Vanden Berghe W, Boone E, Essawi T, Haegeman G (2007) Screening of indigenous Palestinian medicinal plants for potential anti-inflammatory and cytotoxic activity. J Ethnopharmacol 113(3):510–516PubMedCrossRef
80.
Custodio L, Fernandes E, Escapa AL, Fajardo A, Aligue R, Albericio F, Neng NR, Noqueira JM, Romano A (2011) Antioxidant and cytotoxic activities of carob tree fruit pulps are strongly influenced by gender and cultivar. J Agric Food Chem 59(13):7005–7012PubMedCrossRef
81.
Kapadia GJ, Tokuda H, Konoshima T, Nishino H (1996) Chemoprevention of lung and skin cancer by Beta vulgaris (beet) root extract. Cancer Lett 100(1–2):211–214PubMedCrossRef
82.
Kapadia GJ, Rao GS, Ramachandran C, Iida A, Suzuki N, Tokuda H (2013) Synergistic cytotoxicity of red beetroot (Beta vulgaris L.) extract with doxorubicin in human pancreatic, breast and prostate cancer cell lines. J Complement Integr Med 10(1):1–10CrossRef
83.
Corsi L, Avallone R, Cosenza F, Farina F, Baraldi C, Baraldi M (2002) Antiproliferative effects of Ceratonia siliqua L on mouse hepatocellular carcinoma cell line. Fitoterapia 73(7–8):674–684PubMedCrossRef
84.
Levinzon A, Ofir R, Alhasid R, Weyl Ben Harush M (2008) Efficacy evaluation of using carob jam for prevention and treating mucositis in children during bone marrow transplantation. J Oncol Nurs Isr (Hebrew) 17(2):26–31
85.
Ben-Arye E, Lev E, Schiff E (2011) Complementary medicine oncology research in the Middle East: shifting from traditional to integrative cancer care. Eur J Integr Med 3(1):29–37CrossRef
86.
Ben-Arye E, Schiff E, Hassan E, Mutafoglu K, Lev-Ari S, Steiner M, Lavie O, Polliack A, Silbermann M, Lev E (2012) Integrative oncology in the Middle East: from traditional herbal knowledge to contemporary cancer care. Ann Oncol 23(1):211–221PubMedCrossRef
87.
Gorriti A, Arroyo J, Quispe F, Cisneros B, Condorhuaman M, Almora Y, Chumpitaz V (2010) Oral toxicity at 60-days of sacha inchi oil (Plukenetia volubilis L.) and linseed (Linum usitatissimum L.), and determination of lethal dose 50 in rodents. Rev Peru Med Exp Salud Publica 27(3):352–60PubMedCrossRef
Metadaten
Titel
Bridging cross-cultural gaps: monitoring herbal use during chemotherapy in patients referred to integrative medicine consultation in Israel
verfasst von
Limor Almog
Efraim Lev
Elad Schiff
Shai Linn
Eran Ben-Arye
Publikationsdatum
01.10.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 10/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2261-9

Weitere Artikel der Ausgabe 10/2014

Supportive Care in Cancer 10/2014 Zur Ausgabe

Original Article

Evaluation of the Semmes–Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy

Original Article

Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US

Original Article

A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring — supporting patients in their homes

Original Article

Correlates of resistance training in post-treatment breast cancer survivors

Original Article

Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy

Original Article

A controlled cohort study of long-term income in colorectal cancer patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise